{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T14:33:50Z","timestamp":1779114830493,"version":"3.51.4"},"reference-count":37,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.hoc.2018.08.005","type":"journal-article","created":{"date-parts":[[2018,11,26]],"date-time":"2018-11-26T20:17:52Z","timestamp":1543263472000},"page":"163-172","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Cutaneous Involvement of Hematologic Malignancies"],"prefix":"10.1016","volume":"33","author":[{"given":"Nancy","family":"Kaddis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric D.","family":"Jacobsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.hoc.2018.08.005_bib1","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1093\/jnci\/92.15.1240","article-title":"Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995","volume":"92","author":"Groves","year":"2000","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.hoc.2018.08.005_bib2","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/bjd.13582","article-title":"Secondary cutaneous lymphoma: comparative clinical features and survival outcome analysis of 106 cases according to lymphoma cell lineage","volume":"173","author":"Lee","year":"2015","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.hoc.2018.08.005_bib3","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/ijd.13493","article-title":"Secondary cutaneous peripheral T-cell lymphoma, unspecified, with generalized benign-looking dermatitis: a possibly distinct peripheral T-cell lymphoma","volume":"56","author":"Lee","year":"2017","journal-title":"Int J Dermatol"},{"issue":"12","key":"10.1016\/j.hoc.2018.08.005_bib4","doi-asserted-by":"crossref","first-page":"3653","DOI":"10.1182\/blood.V95.12.3653","article-title":"Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment","volume":"95","author":"Bekkenk","year":"2000","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.hoc.2018.08.005_bib5","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1600-0560.2006.00460.x","article-title":"The spectrum of cutaneous lymphomas in Japan: a study of 62 cases based on the World Health Organization Classification","volume":"33","author":"Yasukawa","year":"2006","journal-title":"J\u00a0Cutan Pathol"},{"issue":"7\u20138","key":"10.1016\/j.hoc.2018.08.005_bib6","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1034\/j.1600-0463.2003.11107805.x","article-title":"Langerhans cells - dendritic cells of the epidermis","volume":"111","author":"Romani","year":"2003","journal-title":"APMIS"},{"issue":"2","key":"10.1016\/j.hoc.2018.08.005_bib7","first-page":"87","article-title":"Langerhans cell histiocytosis of the hypothalamus: diagnostic value of immunohistochemistry","volume":"15","author":"Mazal","year":"1996","journal-title":"Clin Neuropathol"},{"issue":"2","key":"10.1016\/j.hoc.2018.08.005_bib8","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/pbc.20425","article-title":"Risk factors for diabetes insipidus in langerhans cell histiocytosis","volume":"46","author":"Grois","year":"2006","journal-title":"Pediatr Blood Cancer"},{"issue":"11","key":"10.1016\/j.hoc.2018.08.005_bib9","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1182\/blood-2010-04-279083","article-title":"Recurrent BRAF mutations in Langerhans cell histiocytosis","volume":"116","author":"Badalian-Very","year":"2010","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2018.08.005_bib10","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1084\/jem.20130977","article-title":"BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups","volume":"211","author":"Berres","year":"2014","journal-title":"J\u00a0Exp Med"},{"issue":"19","key":"10.1016\/j.hoc.2018.08.005_bib11","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1182\/blood-2014-05-577825","article-title":"Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis","volume":"124","author":"Chakraborty","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2018.08.005_bib12","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/(SICI)1096-911X(199701)28:1<9::AID-MPO3>3.0.CO;2-P","article-title":"Langerhans'-cell histiocytosis in adults","volume":"28","author":"Baumgartner","year":"1997","journal-title":"Med Pediatr Oncol"},{"issue":"379","key":"10.1016\/j.hoc.2018.08.005_bib13","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/00003086-200010000-00027","article-title":"Langerhans' cell histiocytosis in patients older than 21 years","author":"Islinger","year":"2000","journal-title":"Clin Orthop Relat Res"},{"issue":"11","key":"10.1016\/j.hoc.2018.08.005_bib14","first-page":"510","article-title":"Langerhans'-cell histiocytosis in 58 adults","volume":"9","author":"G\u00f6tz","year":"2004","journal-title":"Eur J Med Res"},{"issue":"2","key":"10.1016\/j.hoc.2018.08.005_bib15","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jaad.2006.06.010","article-title":"Aggressive histiocytic disorders that can involve the skin","volume":"56","author":"Newman","year":"2007","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.hoc.2018.08.005_bib16","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.leukres.2016.01.012","article-title":"Comparison of vindesine and prednisone and cyclophosphamide, etoposide, vindesine, and prednisone as first-line treatment for adult Langerhans cell histiocytosis: a single-center retrospective study","volume":"42","author":"Duan","year":"2016","journal-title":"Leuk Res"},{"key":"10.1016\/j.hoc.2018.08.005_bib17","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1750-1172-8-72","article-title":"Management of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of Euro-Histio-Net","volume":"8","author":"Girschikofsky","year":"2013","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"10.1016\/j.hoc.2018.08.005_bib18","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/pbc.10464","article-title":"Langerhans cell histiocytosis: a pathologic combination of oncogenesis and immune dysregulation","volume":"42","author":"Egeler","year":"2004","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"10.1016\/j.hoc.2018.08.005_bib19","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.jaad.2013.08.036","article-title":"Emperipolesis is not pathognomonic for Rosai-Dorfman disease: rhinoscleroma mimicking Rosai-Dorfman disease, a clinical series","volume":"69","author":"Chou","year":"2013","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.hoc.2018.08.005_bib20","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1034\/j.1600-0560.2002.290209.x","article-title":"Cutaneous Destombes-Rosai-Dorfman disease: absence of detection of HHV-6 and HHV-8 in skin","volume":"29","author":"Ortonne","year":"2002","journal-title":"J\u00a0Cutan Pathol"},{"issue":"2","key":"10.1016\/j.hoc.2018.08.005_bib21","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1158\/2159-8290.CD-15-0913","article-title":"Diverse and targetable kinase alterations drive histiocytic neoplasms","volume":"6","author":"Diamond","year":"2016","journal-title":"Cancer Discov"},{"issue":"10","key":"10.1016\/j.hoc.2018.08.005_bib22","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/modpathol.2017.55","article-title":"Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosai-Dorfman disease","volume":"30","author":"Garces","year":"2017","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.hoc.2018.08.005_bib23","first-page":"19","article-title":"Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): review of the entity","volume":"7","author":"Foucar","year":"1990","journal-title":"Semin Diagn Pathol"},{"issue":"7","key":"10.1016\/j.hoc.2018.08.005_bib24","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1002\/pbc.25017","article-title":"Updates on histiocytic disorders","volume":"61","author":"Vaiselbuh","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.hoc.2018.08.005_bib25","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.clim.2016.12.006","article-title":"The importance of considering monogenic causes of autoimmunity: a somatic mutation in KRAS causing pediatric Rosai-Dorfman syndrome and systemic lupus erythematosus","volume":"175","author":"Ragotte","year":"2017","journal-title":"Clin Immunol"},{"issue":"4","key":"10.1016\/j.hoc.2018.08.005_bib26","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.prp.2007.01.008","article-title":"Intestinal occlusion caused by Rosai-Dorfman disease mimicking colonic diverticulitis","volume":"203","author":"Long","year":"2007","journal-title":"Pathol Res Pract"},{"issue":"3","key":"10.1016\/j.hoc.2018.08.005_bib27","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/pbc.21606","article-title":"Rosai-Dorfman disease following bone marrow transplantation for pre-B cell acute lymphoblastic leukemia","volume":"51","author":"Ambati","year":"2008","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"10.1016\/j.hoc.2018.08.005_bib28","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/ajh.10008","article-title":"Treatment of sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): report of a case and literature review","volume":"69","author":"Pulsoni","year":"2002","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.hoc.2018.08.005_bib29","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1179\/016164109X12608733393836","article-title":"Diagnosis and management of Rosai-Dorfman disease involving the central nervous system","volume":"32","author":"Adeleye","year":"2010","journal-title":"Neurol Res"},{"issue":"5","key":"10.1016\/j.hoc.2018.08.005_bib30","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/ceo.12476","article-title":"Intralesional steroid for orbital manifestations of Rosai-Dorfman disease","volume":"43","author":"Petrushkin","year":"2015","journal-title":"Clin Exp Ophthalmol"},{"issue":"6","key":"10.1016\/j.hoc.2018.08.005_bib31","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1080\/00016480500452582","article-title":"Extranodal Rosai-Dorfman disease: involvement of eye, nose and trachea","volume":"126","author":"Ottaviano","year":"2006","journal-title":"Acta Otolaryngol"},{"issue":"2","key":"10.1016\/j.hoc.2018.08.005_bib32","first-page":"211","article-title":"Minimal change nephropathy in a 7-year-old boy with Rosai-Dorfman disease","volume":"19","author":"Sakallioglu","year":"2006","journal-title":"J\u00a0Nephrol"},{"key":"10.1016\/j.hoc.2018.08.005_bib33","unstructured":"Diamond EL, Durham BH, Dogan A, et\u00a0al. Phase 2 trial of single-agent cometinib for adults with histiocytic disorders: preliminary results. Presented at the Erdheim Chester Global Alliance Medical Symposium, New York, September 12\u201317, 2016. [abstract: 257]."},{"issue":"24","key":"10.1016\/j.hoc.2018.08.005_bib34","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1056\/NEJMc1713676","article-title":"Rosai-Dorfman disease with activating KRAS Mutation - response to cobimetinib","volume":"377","author":"Jacobsen","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.hoc.2018.08.005_bib35","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1001\/archderm.143.6.736","article-title":"Imatinib as a treatment option for systemic non-Langerhans cell histiocytoses","volume":"143","author":"Utikal","year":"2007","journal-title":"Arch Dermatol"},{"issue":"5","key":"10.1016\/j.hoc.2018.08.005_bib36","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1001\/archdermatol.2008.597","article-title":"A\u00a0case of cutaneous Rosai-Dorfman disease refractory to imatinib therapy","volume":"145","author":"Gebhardt","year":"2009","journal-title":"Arch Dermatol"},{"issue":"26","key":"10.1016\/j.hoc.2018.08.005_bib37","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1182\/blood-2018-03-839753","article-title":"Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease","volume":"131","author":"Abla","year":"2018","journal-title":"Blood"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858818307834?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858818307834?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:11:53Z","timestamp":1760184713000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858818307834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S0889858818307834"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2018.08.005","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cutaneous Involvement of Hematologic Malignancies","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2018.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}